OakChart

Electra Therapeutics Inc

ETRAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

9.45+1.46 (18.27%)
2026-11-12 03:45 CET
Market cap
- USD m
Revenue, TTM
- USD m
Net income, TTM
- USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-
P/E
-
Compare

Price

ETRA against its 20-day averages
20
8.0010.0012.0014.0016.002.6M5.1MVolumeSep 26Oct 26Nov 26ETRAclose 9.4520-day 8.449.4552w high52w low

39.0% under the 52-week high of 15.50 on 18 Sep 2026. 52-week low 6.87 on 4 Nov 2026. Last 15 sessions, 38.2% high to low

Volume 0.65× normal · the line is the 50-bar volume average

Profile

ETRA
52-week range, 30% of the way up
6.8615.50

Electra Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in therapies against novel targets for diseases in immunology and cancer. The company was founded by Adam Rosenthal on October 11, 2018 and is headquartered in South San Francisco, CA.

IPOSep 18, 2026
ATR, 14d1.01
Rel volume0.65
Short float1.26%
Insider own38.62%
Inst own16.78%

Snapshot

6 groups

Valuation

Index-
Market Cap593.15M
Enterprise Value-
Income-
Sales-
Book/sh-
Cash/sh-
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees-
IPOSep 18, 2026

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C-
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio-
Current Ratio-
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-
EPS next Y-
EPS next Q-0.45
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y- -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-
Sales Q/Q-
EarningsSep 02
EPS/Sales Surpr.- -

Ownership

Insider Own38.62%
Insider Trans18.57%
Inst Own16.78%
Inst Trans3.58%
ROA-
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2012.03%
SMA50-1.53%
SMA200-1.53%
Trades-

Technical

Shs Outstand62.77M
Shs Float38.52M
Short Float1.26%
Short Ratio0.81
Short Interest0.48M
52W High15.50 -39.03%
52W Low6.86 37.65%
Volatility15.02% 10.65%
ATR (14)1.01
RSI (14)52.41
Beta-
Rel Volume0.65
Avg Volume595.76K
Volume385,207

Performance

Perf Week18.57%
Perf Month9.76%
Perf Quarter-
Perf Half Y-
Perf YTD-37.00%
Perf Year-
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price33.50
Prev Close7.99
Price9.45
Change %18.27%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Oct 26, 2026InitiatedHH.C. WainwrightBuy$30+217.5%
Oct 22, 2026InitiatedJJP MorganOverweight$36+281.0%
Oct 13, 2026InitiatedTTD CowenBuy
Oct 13, 2026InitiatedJJefferiesBuy$32+238.6%
Oct 13, 2026InitiatedEEvercore ISIOutperform$36+281.0%
Oct 13, 2026InitiatedCCantor FitzgeraldOverweight

Peers

Mkt cap
TickerCompanyMkt cap
ALXOAlx Oncology Holdings Inc154.87M
ANABAnaptysBio Inc1.46B
ACRSAclaris Therapeutics Inc688.38M
ALMSAlumis Inc883.74M
CLDXCelldex Therapeutics Inc2.37B
XNCRXencor Inc3.00B
UPBUpstream Bio Inc175.27M
IMVTImmunovant Inc7.67B
SYRESpyre Therapeutics Inc10.14B
ABVXAbivax ADR8.01B

Insider trading

14 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
GORDON CARL LDirectorNov 06 '26Buy7.8549,416387,9165,230,578Nov 10 08:14 PM
GORDON CARL LDirectorNov 10 '26Buy8.4522,700191,8155,255,278Nov 10 08:14 PM
GORDON CARL LDirectorNov 09 '26Buy8.2420,000164,8005,234,578Nov 10 08:14 PM
ORBIMED ADVISORS LLCDirectorNov 06 '26Buy7.8549,416387,9165,230,578Nov 10 08:09 PM
ORBIMED ADVISORS LLCDirectorNov 10 '26Buy8.4522,700191,8155,255,278Nov 10 08:09 PM
ORBIMED ADVISORS LLCDirectorNov 09 '26Buy8.2420,000164,8005,234,578Nov 10 08:09 PM
GORDON CARL LDirectorNov 03 '26Buy7.86245,1131,926,6065,175,604Nov 05 05:47 PM
GORDON CARL LDirectorNov 05 '26Buy7.31156,0911,141,0255,220,762Nov 05 05:47 PM
GORDON CARL LDirectorNov 04 '26Buy7.5371,367537,4855,189,871Nov 05 05:47 PM
ORBIMED ADVISORS LLCDirectorNov 03 '26Buy7.86245,1131,926,6065,175,604Nov 05 05:39 PM
ORBIMED ADVISORS LLCDirectorNov 05 '26Buy7.31156,0911,141,0255,220,762Nov 05 05:39 PM
ORBIMED ADVISORS LLCDirectorNov 04 '26Buy7.5371,367537,4855,189,871Nov 05 05:39 PM
GORDON CARL LDirectorSep 21 '26Buy15.001,333,33319,999,9955,126,891Sep 23 05:35 PM
ORBIMED ADVISORS LLCDirectorSep 21 '26Buy15.001,333,33319,999,9955,126,891Sep 23 05:29 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
TMEDT. Rowe Price Health Care ETFAUM: 38.55M
VTWGVanguard Russell 2000 Growth Index ETFAUM: 1.41B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
VTHRVanguard Russell 3000 Index ETFAUM: 4.81B

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-09-02-0.830--0.8300.00--
2026Q3---0.454--0.005
2026Q4---0.492--0.006
2027Q1---0.497--0.003
2027Q2---0.537--0.003
2027Q3---0.563--0.004
2027Q4---0.645--0.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
No annual earnings.

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-213000.000.000.00
2026Q3S2026-10-122000.000.000.00
2026Q3S2026-10-091000.000.000.00
2026Q3R2026-10-12200-0.40-0.45-0.34
2026Q3R2026-10-09100-0.34-0.34-0.34
2026Q3E2026-10-23500-0.45-0.56-0.34
2026Q3E2026-10-12400-0.43-0.48-0.34
2026Q3E2026-10-09100-0.34-0.34-0.34

Estimate history

EPS, annual
Period
EPS, quarterly
Period
Sales, annual
Period
Sales, quarterly
Period
Shares, annual
Period
Shares, quarterly
Period

Income statement, annual

No statement data.

Income statement, quarterly

No statement data.

Balance sheet, annual

No statement data.

Cash flow, annual

No statement data.

Balance sheet, quarterly

No statement data.

Cash flow, quarterly

No statement data.

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.26%0.5M38.5M620.39K
2026-10-151.06%0.4M38.5M803.30K
2026-09-302.79%0.7M25.2M1.15M

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-104Statement of changes in beneficial ownership of securities2026-11-06SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-11-054Statement of changes in beneficial ownership of securities2026-11-03SEC
2026-10-29SCHEDULE 13GSEC
2026-09-28SCHEDULE 13GSEC
2026-09-28SCHEDULE 13GSEC
2026-09-25SCHEDULE 13DSEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-214Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-21S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-09-218-KCurrent report2026-09-21SEC
2026-09-213Initial statement of beneficial ownership of securities2026-09-21SEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-18SEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-18SEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-18SEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-18SEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-18SEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-18SEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-18SEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-18SEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-18SEC
2026-09-18CERTSEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-18SEC
2026-09-18424B4SEC
2026-09-188-A12BSEC
2026-09-183Initial statement of beneficial ownership of securities2026-09-18SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-118.70M1200
2026-100000
2026-0940.00M200
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Sanofi3.92%
Jefferies Financial Group Inc.3.58%
VICTORY CAPITAL MANAGEMENT INC0.28%
Monashee Investment Management LLC0.16%
Squarepoint Ops LLC0.07%
Y-Intercept0.03%
UBS Group AG0.00%

Funds

Fund% owned
-

OakChart. ETRA. Cached 15 minutes.

Some panels did not load: news.